Clinical Trial Update: SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating stereotactic body radiotherapy (SBRT) with a PD-1 inhibitor for late-stage or recurrent pancreatic cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• PD-1 inhibitor (unspecified)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Pancreatic Cancer | Phase 1 | Status: TERMINATED